February 2nd, 2008
(
2 Comments)
Pronunciation: dye-eth-ill-PROH-pee-on
Chemical Abstracts Service Registry Number: 90-84-6. (Hydrochloride form134-80-5)
Formal Names: Adiposan, Amfepramone, Anfamon, Apisate, Bonumin, Brendalit, Dietic, Dietil-Retard, DIP, Dobesin, Frekentine, Lineal-Rivo, Linea-Valeas, Lipomin, Liposlim, Magrene, Moderatan, M-Orexic, Nobesine, Nulobes, Prefamone, Propion, Regenon, Regibon, Slim-plus, Tenuate, Tenuate Dospan, Tepanil
Informal Names: Blues
Type: Stimulant (anorectic class). See page 15
Federal Schedule Listing: Schedule IV (DEA no. 1610)
USA Availability: Prescription
Pregnancy Category: B
Read the rest of this entry »
September 27th, 2007
(
1 Comment)
When I studied at school I was quite slim and skinny girl. I ate everything I wanted and never gained any weight. All of my friends envied me as they tried to follow different diets to keep their figures in form but I did not have to do anything to remain thin. I never thought of diets or healthy nutrition as I was sure that my ideal body would be the same in some years and I would never have to search for ways to lose some weight as my friends did.
Read the rest of this entry »
September 15th, 2007
(
1 Comment)
Rimonabant (Acomplia, Zimulti) was created by a French Pharmaceutical Company Sanofi-Aventis or Sanofi-Synthelabo. This medication appeared to be a new method to overcome a problem of weight loss as it is used specially to treat obesity and perhaps some other ailments. The present diet drug was legally approved in the Great Britain on June 28th 2006. At the same time it was approved in other European countries as well as in many countries around the world that made this medicine especially popular in most part of the world. This could become a real reason to expect the FDA approval of Rimonabant (Acomplia, Zimulti) in the United States as well. But there are no guarantees to be certain of it. The FDA became stricter to all medications on the market especially when it concerns new drugs. So Rimonabant (Acomplia, Zimulti) strangely enough is still not approved in the USA. Read the rest of this entry »